ROCHESTER, N.Y., March 24 /PRNewswire/ -- China's State Food and Drug Administration has approved the sale of the pioneering Lucid VivaScope(R) reflective confocal microscope in the Peoples Republic of China, said Jay Eastman, CEO of Lucid, a Rochester, New York-based medical device and information company dedicated to providing improved care for dermatology patients.
Lucid's VivaScope(R) reflective confocal microscopes (RCM) provide non- invasive, in-vivo cellular resolution images of skin. Dermatologists can use the images to form a clinical judgment for a variety of skin conditions -- without the need for surgery to excise tissue -- thus improving the quality of care for their patients.
"Just as MRI and CT scans have largely eliminated the need for routine 'exploratory surgery', the use of Lucid's VivaScope(R) confocal microscopes may one day eliminate the need for routine invasive skin biopsies," Eastman explained.
"This milestone announcement opens opportunities for application of confocal microscopes to evaluate and monitor treatment of skin inflammatory and pigmentation disorders with leading hospitals throughout China," Eastman said.
"I am very pleased to see this positive outcome from a long and detailed review process that will allow us to participate in one of the fastest growing medical markets in the world," he said. "We believe that reflectance confocal microscopes will become a standard clinical tool with its capacity to take painless, non-invasive optical biopsies of a wide range of skin lesions and disorders."
Sales of Lucid's VivaScope(R) confocal microscopes in China will be handled by ConBio (China) Co., Ltd, Eastman said.
Dr. Qiushi Ren, CEO, ConBio said, "We are excited by the opportunity to introduce Lucid's unique, leading RCM technology to Chinese doctors and building our business together."
Founded in 1996, ConBio is a multi-specialty health care company
focused on providing innovative
|SOURCE Lucid, Inc.|
Copyright©2008 PR Newswire.
All rights reserved